Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17771175 | 0.86 | ALDH1A1 (0.34) | CA12CA7CA9CA14ALDH1A1 | |
| SCHEMBL19996803 | 0.81 | KCNA5 (0.33) | KCNA5 | |
| SCHEMBL12988956 | 0.81 | GRIA4 (0.42) | CA12CA7CA9CA14ALDH1A1 | |
| SCHEMBL22941135 | 0.79 | CA12 (0.39) | CA12CA7CA9CA14ALDH1A1 | |
| SCHEMBL14196188 | 0.79 | CA12 (0.35) | CA12CA7CA9CA14ALDH1A1 | |
| SCHEMBL13585681 | 0.78 | PMP22 (0.50) | — | |
| SCHEMBL1769662 | 0.78 | PMP22 (0.50) | — | |
| SCHEMBL26724824 | 0.77 | CA1 (0.46) | CA12CA7CA9CA14KCNA5 | |
| SCHEMBL12194930 | 0.77 | RELA (0.39) | CA12CA7CA9CA14ALDH1A1 | |
| SCHEMBL777392 | 0.77 | CA12 (0.39) | CA12CA7CA9CA14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | Memorial Slooan-Kettering Cancer Center (US) | 2019-02-07 | — | — | US | disclosed |
| US-9926321-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2018-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | CA12 3083/4885CA7 1611/4885CA9 927/4885 |
| US-20190038656-A1 | ANTHRANILYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ATIC, SLC35B2, ADORA1 | CA12 3083/4885CA7 1611/4885CA9 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.